Market Currents
Biogen's (BIIB) BG-12 compound for multiple sclerosis "demonstrated significant and clinically...
-
Thursday, September 20, 2012, 9:46 AM ETBiogen's (BIIB) BG-12 compound for multiple sclerosis "demonstrated significant and clinically meaningful reductions" in relapses and brain lesions in patients with relapsing-remitting MS, data from two Phase III trials show. BG-12 also slowed the progress of the disease. The drug could be on track to become the third oral medicine for MS, as well as the safest and most effective. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
